Gastrointestinal stromal tumours (GIST) - 17 years experience from Mid Trent Region (United Kingdom)

European Journal of Surgical Oncology

Volumn 34, Issue 4, 2008, Pages 445-449

  Ahmed, I ^a   Welch, N T ^a   Parsons, S L ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

CD117; Gastrointestinal stromal tumour; GIST; Recurrence; Resection margins

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL TYPE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MITOSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL MORTALITY; TUMOR RECURRENCE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 40749149463     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.01.006     Document Type: Article

References (27)

1. Mazur M.T., and Clark H.B. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 7 (1983) 507-519
2. Schaldenbrand J.D., and Appleman H.D. Solitary solid stromal tumors in gastrointestinal tumors in Von Recklinghausen's disease with minimal smooth muscle differentiation. Hum Pathol 15 (1984) 229-232
3. Miettinen M., Virolainen M., and Sarlomo-Rikala M. Gastrointestinal stromal tumors: value of CD34 in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 19 (1995) 207-216
4. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
5. Kindblom L.-G., Remotti H.E., Aldenborg F., and Meis-Kindblom J.M. Gastrointestinal pacemaker cells (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of interstitial cells of Cajal. Am J Pathol 152 (1998) 1259-1269
6. Sircar K., Hewlett B.R., Huizinga J.D., Chorneyko K., Berezin I., and Riddell R.H. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23 4 (1999) 377-389
7. Nishida T., and Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 15 (2000) 1293-1301
8. Novartis Pharma AG. Basel, Switzerland; 2002.
9. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 (2002) 459-465
10. Rossi C.R., Mocellin S., Mencarelli R., et al. Gastrointestinal stromal tumours: from a surgical to a molecular approach. Int J Cancer 107 2 (2003) 171-176
11. Dematteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., and Brennan M.F. Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
12. Demetri G. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 38 (2002) S52-S59
13. Langer C., Gunawan B., Schuler P., Huber W., Fuzesi L., and Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 90 (2003) 332-339
14. Koch S., and Besuch P. Gastrointestinal stromal tumours - retrospective classification of mesenchymal tumours of the gastrointestinal tract. DGHO (2003). http://www.cancerimprovement.nhs.uk/%5Cdocuments%5Cupper_gi%5Cpathways%5CGIST_Mngmnt7.pdf http://www.cancerimprovement.nhs.uk/%5Cdocuments%5Cupper_gi%5Cpathways%5CGIST_Mngmnt7.pdf
15. Urbanczyk K., Limon J., Korobowicz E., et al. Gastrointestinal stromal tumours. A multicenter experience. Pol J Pathol 56 2 (2005) 51-61
16. Wong N.A., Young R., Malcomson R.D., et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. : Histopathology 43 2 (2003) 118-126
17. Fujimoto Y., Nakanishi Y., Yoshimura K., and Shimoda T. Clinicopathologic study of primary malignant gastrointestinal tumour of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric cancer 6 1 (2003) 39-48
18. Orosz Z., Tornoczky T., and Sapi Z. Gastrointestinal stromal tumours: a clinicopathologic and immunohistochemical study of 136 cases. Pathol Obcol Res 11 1 (2005) 11-21
19. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumours of the stomach: a clinicopathological, immunohistochemical and molecular genetic study of 1765 cases with long term follow-up. Am J Surg Pathol 29 1 (2005) 52-68
20. Connolly E.M., Gaffney E., and Reynolds J.V. Gastrointestinal stromal tumours. Br J Surg 90 (2003) 1178-1186
21. TA086 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours. Technology Appraisal 86. National Institute for Clinical Excellence; October 2004. .
22. Judons I., Leahy M., Whelan J., et al. A guideline for the management of gastrointestinal stromal tumour (GIST). Sarcoma 6 (2002) 83-87
23. DeMatteo R.P., Heinrich M.C., and El-Rifai W.M. Clinical management of gastrointestinal stromal tumours: before and after STI-571. Human Pathology 33 (2002) 466-477
24. Lehnert T. Gastrointestinal sarcoma (GIST) - a review of surgical management. Ann Chir Gynaecol 87 (1998) 297-305
25. Demetri G.D., von Mehren M., and Blanke C.D. Efficacy and safety of imatinib mesylate in advanced gastrointestinal tumours. N Engl J Med 347 7 (2002) 472-480
26. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
27. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 (2003) 2006-2011